CORT stock drops after appeals court sides with Teva in Korlym patent fight
・Corcept’s mifepristone product Korlym was approved by the FDA in 2012 to treat Cushing’s syndrome and subsequently, in 2020, Teva got the agency’s approval to market a generic version of the drug. ・Corcept appealed a decision from the United...
Stocktwits